Bio-Rad Laboratories Class A
330 hedge funds and large institutions have $5.87B invested in Bio-Rad Laboratories Class A in 2019 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 104 increasing their positions, 130 reducing their positions, and 52 closing their positions.
321% more call options, than puts
Call options by funds: $20.4M | Put options by funds: $4.84M
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
1% less capital invested
Capital invested by funds: $5.94B → $5.87B (-$78.6M)
2.31% less ownership
Funds ownership: 78.22% → 75.91% (-2.3%)
5% less funds holding
Funds holding: 346 → 330 (-16)
20% less repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 130
25% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$44.2M |
| 2 |
Millennium Management
New York
|
+$31.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$28.7M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$24.6M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$157M |
| 2 |
N
Natixis
Paris,
France
|
-$28.5M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$27.9M |
| 4 |
Morgan Stanley
New York
|
-$26.9M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$26.2M |
BIO Hedge Fund Activity: Q2 2019 in Review
330 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2019, worth a combined $5.87B — down 1.3% from $5.94B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of BIO and 39 opened new positions — a net loss of 13 holders — while 130 trimmed existing stakes and 104 added.
The largest buyer was Point72 Asset Management, adding an estimated $44.2M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $157M sold.
- 330 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2019, down from 346 in Q1 2019.
- Funds reported $5.87B of Bio-Rad Laboratories Class A stock for Q2 2019, down 1.3% quarter-over-quarter.
- 39 funds opened new Bio-Rad Laboratories Class A positions in Q2 2019 and 52 closed out, a net change of -13 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q2 2019 was Point72 Asset Management, an estimated $44.2M added.
- The largest Bio-Rad Laboratories Class A seller in Q2 2019 was Acadian Asset Management, an estimated $157M sold.
Based on aggregated 13F filings for Q2 2019.